1 citations
,
January 2023 in “Cutis” The paper concludes that the new medication baricitinib needs further testing in a more diverse group of patients with alopecia areata.
24 citations
,
April 2007 in “European Journal of Pharmaceutics and Biopharmaceutics” Microparticles containing artocarpin extract could effectively treat hair loss and acne with minimal side effects.
6 citations
,
June 2022 in “Frontiers in Bioengineering and Biotechnology” The gel with icariin speeds up wound healing, reduces scarring, and helps hair growth by controlling BMP4 signaling. It also reduces inflammation and improves wound quality in mice, adapts to different wound shapes, and gradually releases icariin to aid healing. It also prevents too much collagen and myofibroblast formation during skin healing.
May 2023 in “Journal of Cosmetic Dermatology” Androgenetic alopecia is linked to higher cardiovascular and metabolic risks, possibly due to irisin resistance.
4 citations
,
February 2024 in “Anais Brasileiros de Dermatologia” June 2025 in “British Journal of Dermatology” Irish dermatologists urgently need guidelines for using JAK inhibitors in treating alopecia areata.
July 2025 in “Journal of Investigative Dermatology” Upadacitinib effectively treats pyoderma gangrenosum.
13 citations
,
April 2025 in “International Journal of Nanomedicine” The new gallic acid hydrogel speeds up wound healing and reduces scarring.
21 citations
,
March 2015 in “Neurological Sciences” A new genetic mutation linked to CARASIL syndrome and small artery disease was found in a Chinese family.
June 2024 in “Current Developments in Nutrition” KeraGLO improves skin and hair health.
18 citations
,
August 2012 in “Chinese journal of integrative medicine/Chinese Journal of Integrative Medicine” Both treatments for alopecia areata are equally effective and safe.
25 citations
,
May 2020 in “Stem Cells Translational Medicine” ADSC-CE treatment safely increases hair density and thickness in androgenetic alopecia patients.
June 2024 in “Journal of Clinical Oncology” Dalpiciclib is the safest and most satisfying CDK4/6 inhibitor for advanced breast cancer patients in China.
42 citations
,
April 2021 in “Journal of clinical pharmacology” Baricitinib helps treat several diseases, including COVID-19, but has side effects and needs careful monitoring.
November 2025 in “Journal of Diabetes Investigation” Dapagliflozin improved blood sugar control in a man with Werner syndrome without side effects.
25 citations
,
October 2019 in “JAAD Case Reports” Baricitinib helped a woman with severe hair loss regrow almost all her hair without side effects.
March 2008 in “The Knowledge Bank (The Ohio State University)” SARM-induced changes in the androgen receptor are specific to each ligand and affect stability and protein interactions.
16 citations
,
January 2003 in “Nuclear Receptor Signaling” Androgens and SARMs play a role in body mass, frailty, skin health, and hair growth, and are used in treating prostate cancer, acne, and hair loss, with potential for new uses and improved versions in the future.
January 2023 in “Cutaneous and Ocular Toxicology”
September 2025 in “Experimental & Molecular Medicine” Small molecules KY19382 and KY19334 may help treat skin cancer by reducing CDK1 levels and blocking harmful cell signals.
June 2024 in “Neuromuscular Disorders” Baricitinib successfully treated myasthenia gravis and alopecia in a patient.
January 2010 in “Yearbook of Endocrinology” Two new compounds can block androgen receptor activity in different ways and may lead to new treatments for androgen-related diseases.
15 citations
,
September 2018 in “Hearing research” Rapamycin reduces age-related hearing cell loss in mice, but acarbose does not.
1 citations
,
February 2025 in “Toxicology in Vitro” Diphlorethohydroxycarmalol may help treat hair loss better than current medications.
December 2022 in “Scientific Reports” Compound 4 is a promising treatment for hair loss with low toxicity.
142 citations
,
March 2019 in “Frontiers in Cellular Neuroscience” The document concludes that adenosine receptor agonists have potential for treating various conditions, but only a few are approved due to challenges like side effects and the need for selective activation.
January 2025 in “Geneesmiddelenbulletin” Baricitinib is effective and safe for treating severe alopecia areata with ongoing use.
April 2025 in “Cosmetics” RCDP NCs are promising anti-aging cosmetic ingredients that improve skin health by reducing oxidative stress and enhancing cell function.
June 2026 in “Frontiers in Immunology” Upadacitinib effectively treated severe atopic dermatitis, vitiligo, and alopecia areata in one patient.